Edition:
United States

AB Science SA (ABS.PA)

ABS.PA on Paris Stock Exchange

13.98EUR
11:35am EDT
Change (% chg)

€-0.22 (-1.55%)
Prev Close
€14.20
Open
€14.20
Day's High
€14.30
Day's Low
€13.94
Volume
47,484
Avg. Vol
178,348
52-wk High
€19.90
52-wk Low
€8.62

ABS.PA

Chart for ABS.PA

About

AB Science SA, also known as AB Science, is a France-based pharmaceutical company specialized in the research, discovery, development and marketing of protein kinase inhibitors (PKIs). It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer,... (more)

Overall

Beta: 1.63
Market Cap(Mil.): €521.01
Shares Outstanding(Mil.): 36.69
Dividend: --
Yield (%): --

Financials

  ABS.PA Industry Sector
P/E (TTM): -- 36.15 37.05
EPS (TTM): -0.78 -- --
ROI: -165.70 15.11 14.35
ROE: -- 16.17 15.56

BRIEF-Ab Science action plan following warning letter validated by FDA

* Announces that the FDA informed AB Science that it trusts the action plan implemented to address the FDA warning letter and to comply with FDA regulations Source text: http://bit.ly/29H6m3g Further company coverage: (Gdynia Newsroom)

Jul 14 2016

BRIEF-AB Science announces FDA approval compassionate use of masitinib in amyotrophic lateral sclerosis

* AB Science announces that FDA approves first compassionate use of masitinib in amyotrophic lateral sclerosis Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jul 11 2016

BRIEF-Ab Science: Updates on marketing authorization application of masitinib

* Annouces that review of conditional marketing authorization application of masitinib in amyotrophic lateral sclerosis (als) will follow standard timeline of EMA

Jul 04 2016

BRIEF-AB Science: Rapporteurs appointed by EMA have recommended filing of masitinib in ALS for conditional marketing authorization

* Rapporteurs appointed by EMA have recommended filing of masitinib in amyotrophic lateral sclerosis (ALS) for conditional marketing authorization

Jun 06 2016

BRIEF-Ab Science submits to EMA the marketing authorization application for masitinib

* Has submitted to EMA the marketing authorization application for masitinib in the treatment of severe systemic mastocytosis

May 02 2016

BRIEF-AB Science FY operating loss widens to 26.0 million euros

* FY revenue 2.3 million euros ($2.63 million) versus 2.1 million euros year ago

Apr 29 2016

BRIEF-Ab Science announces success of a private placement

* Twelve million euro ($13.5 million) raised through a private placement of 764,820 shares

Apr 18 2016

BRIEF-Ab Science launches share capital increase

* Said on Sunday, it launched a share capital increase by way of accelerated book building

Apr 18 2016

BRIEF-AB Science announces positive interim results from phase 3 trial of masitinib

* AB Science announces positive interim results from phase 3 trial of masitinib in amyotrophic lateral sclerosis (ALS)

Apr 04 2016

BRIEF-Ab Science underscores potential of masitinib in neurological and neurodegenerative diseases

* New independent publications underscore the potential of masitinib in neurological and neurodegenerative diseases Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Mar 10 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.